JP Morgan Chase’s Achillion Pharmaceuticals ACHN Stock Holding History

JP Morgan Chase’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,000	Closed	-$48K	–	6188
2018 Q4	$48K	Buy	+30,000	New	+$84.8K	﹤0.01%	5101

JP Morgan Chase's ACHN Position: Q1 2020 in Review

JP Morgan Chase sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 73,726 shares — an estimated $445K sold.

JP Morgan Chase first reported a position in ACHN in Q2 2013 and held it in 24 quarters. The position peaked at $11.9M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

JP Morgan Chase reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
JP Morgan Chase sold 73,726 Achillion Pharmaceuticals shares in Q1 2020, an estimated $445K.
JP Morgan Chase first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 24 quarters.
JP Morgan Chase's Achillion Pharmaceuticals position peaked at $11.9M in Q4 2015.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.